Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 324 In stock
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 MnrMSpVv[3Srb36gRZN{[Xl? M131e|AvP87:TR?= NFfDboszPGh? M2ixOIV1cGGwb3y= NWjz[ZZ5\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?= M3XtOFI2Pzh5MEe5
TE13 MkG4SpVv[3Srb36gRZN{[Xl? NF7tU5UxNjQQvF2= MVKyOIg> Mo\4eZAuemWpdXzheIV{KFKDU2PGOWEhdGW4ZXy= MmHNNlU2Pzl4NkW=
TE13 NXv4UXpJSXCxcITvd4l{KEG|c3H5 NYj6T|k3OC5|zszN MXGyOIg> M{K5NYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? NGr1ZYszPTV5OU[2OS=>
MEFs NGTTZohHfW6ldHnvckBCe3OjeR?= MlnvOe69VQ>? MXKxOog> M1O5[Ylv[3KnYYPld{B1cGViRWDFR{BifHSjY3jt[Y51NCCWaYKg[IVtcX[ncomgZY5lKHSqZTDl[oZq[2mnbnP5JI9nKHCnZHXzeIFtKG[xcn3heIlwdg>? NEHQb3IzPTR6Mk[zOC=>
SW480  M1r5emZ2dmO2aX;uJGF{e2G7 MWmwMlHPxE1? MXy0PIg> MUTEUXNQ NUDMcotDemW4ZYLz[ZMhTU2W M4f2SVI2PDN2OUm3
PC3  NF:xUIpHfW6ldHnvckBCe3OjeR?= NI[4W3AxNjIQvF2= NYe0dno4PDiq NGKw[mZFVVOR NGnpbnNz\X[ncoPld{BGVVR? Mm\1NlU1OzR7OUe=
SW480  NY[4c3ZpTnWwY4Tpc44hSXO|YYm= M{C5VVAvOc7:TR?= NYPBWno5PDiq NX;ZNpBDTE2VTx?= M4XKfYF1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= NFS1e|gzPTR|NEm5Oy=>
PC3  M1vTVWZ2dmO2aX;uJGF{e2G7 M4jXbFAvOc7:TR?= NWPKTIFsPDiq Mn\uSG1UVw>? M3;YXoF1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= MWOyOVQ{PDl7Nx?=
SW480  M4XPbmZ2dmO2aX;uJGF{e2G7 NIHCVHExNjIQvF2= M37oWlQ5cA>? MWXEUXNQ Mn7ZbY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? NWXse4xVOjV2M{S5PVc>
PC3  M{XXNWZ2dmO2aX;uJGF{e2G7 NGPyR3AxNjIQvF2= NYTxb|diPDiq NIGx[I5FVVOR MX\pcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz M4rXcFI2PDN2OUm3
A431 NEPoXGtCeG:ydH;zbZMhSXO|YYm= MWiyM|ExNzVyL{GwNI5O M3H6WVQ5cA>? M3nCR2ROW09? NXn2d2RCcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4To M2H4NFI2OzdzME[5
A431 MV3GeY5kfGmxbjDBd5NigQ>? MYm1NI5O MkPzNk83NzF{L{K0bC=> M1:1bWROW09? MmHKZYN1cX[jdHXzJJAzOSCjbnSgbY5pcWKrdIOgRXRHOyCneIDy[ZN{cW:w MV[yOVM4OTB4OR?=
MDA-MB-231 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvpR4lDOC14MEDuUS=> NG\5d4ozPGh? Mmm4SG1UVw>? NWrYdGgyUUN3MDDv[kAyODCwTR?= MVOyOVE6Ojd{MR?=
MCF7 NXq2e2tpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv3c2gxNTZyMH7N NHTtZ3UzPGh? NGTpXYhFVVOR NEWy[FZKSzVyIH;mJFc2dk1? NXHmPWpuOjVzOUK3NlE>
SKOV-3 NV2yWnBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGxUIIyNTFyzszN NUfnT21oOjSq NF3p[lZFVVOR M3yyOmlEPTBib3[gOU43|ryP MYGyOVE3QTR7MR?=
A549 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3i1V|EuOTEQvF2= M{\qVlI1cA>? NHOwZ4xFVVOR NW[2emxDUUN3MDDv[kA{NjMQvF2= NWrSToREOjVzNkm0PVE>
SKOV-3 NUH5PIpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:wMlEuOc7:TR?= M17WPVQ5cA>? NIq0c29FVVOR MYnJR|UxKG:oIECuO:69VQ>? MWCyOVE3QTR7MR?=
A549 M{W1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjUXZgzOC5zLUJOwG0> MlKxOFhp MnuxSG1UVw>? NIfwfpdKSzVyIH;mJFAvOjkQvF2= MlHENlUyPjl2OUG=
SKOV-3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSwMlAyNTBwOd88US=> NFTlb204Omh? M4K5U2ROW09? M2DKT2lEPTBib3[gNE4{Os7:TR?= NFW0emMzPTF4OUS5NS=>
A549 M1GwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWwMlAyNTBwOd88US=> MkO5O|Jp M2LsbWROW09? NGHZZVFKSzVyIH;mJFAvODcQvF2= MVmyOVE3QTR7MR?=
HeLa MlXHSpVv[3Srb36gRZN{[Xl? NF;3PXczPTCwTR?= MWGxOog> M3\4XmROW09? MnHybY5kemWjc3XzJGN[WDGDMTDtVm5CKGW6cILld5Nqd28EoB?= MYCyOVEyPjZ6OB?=
CNE2 NFHrPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfRNVAxNTZyMH7N NWjy[WpHOjRxNEivO|Jp Mm\PbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVqyOFk3QTlyMR?=
PC3 MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DUSFExOC1zMECwcm0> NVTETlJFOjSq M1rhemlEPTBib3[gN|Axdk1? MmfnNlQ5PTR4NUi=
LNCaP NX33W3VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[5S5A4OTByLUGwNFBvVQ>? MV2yOIg> MnTRTWM2OCCxZjCzNFBvVQ>? NEG3WYYzPDh3NE[1PC=>
HeLa  NHvqWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4n4RVLPxE1? NVyyUnB3PDiq MUHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliYXLveZQhOjVn MYKyOFg1PjF|NR?=
HMEC-1  M1O4OGZ2dmO2aX;uJGF{e2G7 MnS4N|Axdk1? NUPLeGY1OjSq MlfHbY5kemWjc3XzJIV5eHKnc4Ppc44hd2cEoG\FS2ZTO8LibWLORS=> MXeyOFcyODZ|MR?=
HeLa MkTSSpVv[3Srb36gRZN{[Xl? MXuxcW0> MoX5NE42cA>? NFHBeldi[m:uaYPo[ZMhfGinIITveIFtKEiGQVOgZYN1cX[rdIm= NUKydVh2OjR5MEe0O|Q>
ACP02 MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzMNlUxNzN3MD:1NFBvVQ>? M2HnSlI1cA>? NUnyW5Z5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= NFLRVHQzPDZ4OEW0Oy=>
ACP03 NV\jNnBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jiOlI2OC9|NUCvOVAxdk1? Mor1NlRp M3y0bYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? NHW2cYgzPDZ4OEW0Oy=>
U87 GBM NHPKcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T0VVExOC9|MECvOVAxKG6P M2GwN|czKGh? MknJNVAxLSCndHjhco9t M1P0NZJm\HWlZYOgcYVidiClZXzsJI52dWKncjDifUA{OSxiNUSsJIFv\CB3ONMgKS=> M4P3SFI1PDZ2OESx
U87 GBM MX7GeY5kfGmxbjDBd5NigQ>? MXSxNFAwPTByIF7t NGn0e4M1QCCq NHHxcWQyODBnIHX0bIFvd2x? Mm\qTY5lfWOnczDT[Y5me2OnbnPlMWxqc2ViQXz0[ZJifGmxboOgbY4hVnWlbHXhdkBOd3KyaH;sc4d6 MYCyOFQ3PDh2MR?=
RPE NX3ycIVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LNNlAvOi9yLkSvNE45NzFizszN MXOyOE81QC95MjDo M{HZ[WROW09? NVOy[JRKcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44h[nliY3XscEBkgWOuZTDhdpJme3R? NG\ZWnQzPDR3Nk[wNi=>
HT29  MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz5NVgxKG6P NGrWSIE4OiCq NV3qeVJFUUN3MDDv[kAyQDBibl2= MmnPNlQ{Pjh{NkW=
hMSCs MoD5SpVv[3Srb36gRZN{[Xl? MWG2MlI2KG6P MYOyOEBp MkjPSG1UVw>? MV7zeIFjcWyrenXzJGhqe3SxbnWgRYNmfHmuYYTpc44h[W6mIITo[UBGgHC{ZYPzbY9vKG:oIGDseZJqeG:2ZX70JGdmdmW| NHnkNoMzPDNzMkO1Oi=>
Huh7  NXvaNXNxTnWwY4Tpc44hSXO|YYm= NYjVcI9xOC5zL{CuOU8yNjBizszN MkfhNlRp NGLGdWF{fXCycnXzd4V{KFmWSFTDNkBo\W6nIHX4dJJme3Orb36= Mn3jNlQzPjl4N{K=
SKOV3 M4LMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXLboUxNjB3LUKg{txO MofuNVAwOjRxNEigbC=> NXPuXJBUTE2VTx?= NIDEe5Fu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MkfzNlQzOjN6MEG=
A2780 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCwMlA2NTJizszN MYqxNE8zPC92ODDo NHPtO3hFVVOR M3nmbI1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NI\sTFkzPDJ{M{iwNS=>
SRA01/04  M{jQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUewMlIh|ryP NH[4fXA1QCCq M4TiOmROW09? M1PzZpN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ MYSyOFE2Pzh5OB?=
HLEB3 NX7ZfXNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT0e4UxNjJizszN Ml;QOFghcA>? M3rOR2ROW09? MlLrd5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM> MmHhNlQyPTd6N{i=
SRA01/04  MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSwMlQwOC56IN88US=> NX\yNIhOPDhiaB?= M1PaOmROW09? M3uxe4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MkT5NlQyPTd6N{i=
HLEB3 MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfPcHExNjRxMD64JO69VQ>? NWL5UnhVPDhiaB?= MkK2SG1UVw>? NILyXYtqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NITFXWEzPDF3N{i3PC=>
HCT116 NGqy[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKwMlIh|ryP MVexNkBp M2K3Z4VvcGGwY3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgdoFlcWG2aX;u MX:yOFEzOjJ|MR?=
CA46 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TqOVMwPi9zMj:yOE81QCCwTR?= NGqxVJk1QCCq MoqxbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCjdDCyOEBidmRiNEigcm3DqA>? NXPpUGdWOjRyNkS5OVE>
PMNs MXjGeY5kfGmxbjDBd5NigQ>? M{nxd|MxKG6P MmP3OFghcA>? NWXS[4lDcW6qaXLpeJMh\W[oZYLvZ5l1d3OrczygTGRCSyCjY4Tpeol1gSCjbnSgVoFkKGGldHn2bZR6 Mk\VNlM6QDh4MUe=
H1299 M3XWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnwNeKh|ryPwrC= NFvCToUzPC92OD:3NkBp NF[w[G5mfGijbn;s NYHxVFVIcW6lcnXhd4V{KGOnbHyg[IVifGhiYX\0[ZIhOjSq NHfNOoUzOzlzNk[wPS=>
A549 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUGwMlI2NzBwNT:xJO69VQ>? NX7ZUZA4OjRxNEivO|IhcA>? NGK4RYlmfGijbn;s MmnybY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MVuyN|g3Pzl7MR?=
H1299 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHiNE4zPS9yLkWvNUDPxE1? MXyyOE81QC95MjDo MUHleIhidm:u NHjXc5BqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MkH2NlM5Pjd7OUG=
A549 MleyRZBweHSxc3nzJGF{e2G7 MVywMlUwOSEQvF2= MVG0PEBp M4LBO4V1cGGwb3y= MYPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NEnqNmkzOzh4N{m5NS=>
H1299 Mk\PRZBweHSxc3nzJGF{e2G7 NXz5RlZkOC53L{Gg{txO NXLWcXVkPDhiaB?= MoG5[ZRp[W6xbB?= MYPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MViyN|g3Pzl7MR?=
SUM149PT M4Hjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlKwNk84NjVxMUCg{txO NV3UNmw6PDhiaB?= MkS2SG1UVw>? M4L4c4lv\HWlZYOgZ4VtdCCmZXH0bEBifCB{IN88UUBqdnOnboPpeIl3\Wy7 NWO5U4E3OjN5OUK2N|g>
SUM190PT NIPpR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULaXY1vPTBxMUCwM|I2OCCwTR?= NX[5dZduPDhiaB?= NIrF[YdFVVOR NGjueVhqdmS3Y3XzJINmdGxiZHXheIgh[XRiNUCgcm0he2Wwc3n0bZZmdHl? NUL1V|AxOjN5OUK2N|g>
HCT1 M{H2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLJNE4zNzFwMD:1MlAh|ryP NWTTN4ZKOTJxMkSvN|YwPDhiaB?= MY\pcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M3;4R|I{PzdyMECw
Lovo M1nUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrrXIlxOC5{L{GuNE82NjBizszN NFz4SWoyOi9{ND:zOk81QCCq M4jBZ4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NHToTXQzOzd5MECwNC=>
AGS MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TXdVAvODF3LUGg{txO MYK3NkBp M2PybIlv\HWlZYOgZ4VtdCCmZXH0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MVyyN|c1PTB{NB?=
Huh7 NUXnWFJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLwVGEyKM7:TR?= MUKyOEBp MlfjSG1UVw>? M{\iN5Jm\HWlZYOgZYJwfXRiMkClJJZq[WKrbHn0feKh NGTURWwzOzZ2M{mzNy=>
ECC1 NWrHZo1wTnWwY4Tpc44hSXO|YYm= M3vENFUxOCCwTR?= MoHIOUBl NV7wdXBWTE2VTx?= NGLuPXlqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= MkDnNlM2OzB5Nkm=
HEC1A NG[2fGJHfW6ldHnvckBCe3OjeR?= NFHFWmY2ODBibl2= NWrzTJJmPSCm MXPEUXNQ M3jJS4lv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF MWeyN|U{ODd4OR?=
EN1 NX33eHdMTnWwY4Tpc44hSXO|YYm= M4X6b|UxOCCwTR?= NYfSWWZCPSCm M3XjV2ROW09? M3PiT4lv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF M3zZRVI{PTNyN{[5
MFE296 M2Llb2Z2dmO2aX;uJGF{e2G7 NFP0eWs2ODBibl2= M1T1U|Uh\A>? MVfEUXNQ MXPpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NXTGOnFPOjN3M{C3Olk>
HASMCs MXrGeY5kfGmxbjDBd5NigQ>? NVXtXW1rOC13MECgcm0> NEf6UXI3KGR? MYrkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKQVTDJIFv\CClZXzsJJZq[WKrbHn0fS=> NVjhfm9HOjN3MUi0Olc>
U373 M4f5[2Z2dmO2aX;uJGF{e2G7 NHjaSFYxNjJ3L{CuOU8yKM7:TR?= Mn;HNlQhcA>? NYXaWXRHcW6lcnXhd4V{KFCULVKg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2SXqjZFO= NHLpSZEzOzR5NEG3NS=>
ARN8  MmrLSpVv[3Srb36gRZN{[Xl? M1GxUlAvODVvMjFOwG0> M3j1U|I1KGh? M4m3fZJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDwOVMu\GWyZX7k[Y51KGenbnXzJIJ6KE63dHzpck0{ MUWyN|Q4ODV2MB?=
MCF7 MnG0SpVv[3Srb36gRZN{[Xl? NWrlPXlHOC5yNT2yJO69VQ>? NUXHWVhLOjRiaB?= NI[0NWRz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? MkjoNlM1PzB3NEC=
H1299  NGK1cFJHfW6ldHnvckBCe3OjeR?= MlP5NE4{O+LCk{JCpOK2VQ>? M1PydFI1NzR6IHi= NX7RXoU{TE2VTx?= MmfsbY5kemWjc3XzJGUu[2GmaHXybY4heHKxdHXpckBt\X[nbIOg[I9{\SCmZYDlcoRmdnSueR?= MWOyN|Q3OTl5NR?=
H1299 MlflSpVv[3Srb36gRZN{[Xl? NXzFVFZMOC53IN88US=> MVq0PEBp NVS0e5pJTE2VTx?= MWLpcohq[mm2czD0bIUhdWmpcnH0c5J6KHCxdHXueIlidCClb33ibY5mKHerdHigd4ltcWKrbnnu M4HORVI{PDZzOUe1
H1299 NYLWcJBPTnWwY4Tpc44hSXO|YYm= NEL3[noxNjVizszN MX:0PEBp NXfOeZJbTE2VTx?= NVfONFhMcW6qaXLpeJMhfGinIHnueoF{cX[nbnXzd:KhKGOxbXLpcoUhf2m2aDDzbYxq[mmwaX6= MXeyN|Q3OTl5NR?=
MG-63  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq5NE4{KM7:TR?= MYCxNk06PiCq Mnv4SG1UVw>? NIjiPVNqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu MlzINlM1PTF6MUe=
LM8 NYTofWZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWewMlMh|ryP M2X2UFEzNTl4IHi= NInyPVlFVVOR NW\mXnR{cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> Mo\4NlM1PTF6MUe=
K562 MVjGeY5kfGmxbjDBd5NigQ>? MYWwMlUh|ryP M1nTWVI1KGh? M4XL[4V1cGGwb3y= MVnk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> MX[yN|Q{ODl3Nx?=
HEL NEfpW5ZHfW6ldHnvckBCe3OjeR?= MV6wMlUh|ryP MWOyOEBp M4LUeoV1cGGwb3y= MUHk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> NFTGRpkzOzR|MEm1Oy=>
HL60 M3zabmFxd3C2b4Ppd{BCe3OjeR?= NEX0OIkyKM7:TR?= M{XHdVI1KGh? MonDbY5lfWOnc9MgZ4VtdCCmZXH0bC=> NIjmemgzOzRyMEWxPS=>
KG1 M3;Me2Fxd3C2b4Ppd{BCe3OjeR?= NFLlSnYyKM7:TR?= NVvIO3ZoOjRiaB?= MYHpcoR2[2W|wrDj[YxtKGSnYYTo M1nzNFI{PDByNUG5
Kazumi NFXMZ2hCeG:ydH;zbZMhSXO|YYm= M4PCT|Eh|ryP MmLuNlQhcA>? MYPpcoR2[2W|wrDj[YxtKGSnYYTo NF3lO4wzOzRyMEWxPS=>
K562 NFjzU21CeG:ydH;zbZMhSXO|YYm= MXKxJO69VQ>? M2jQ[lI1KGh? MojQbY5lfWOnc9MgZ4VtdCCmZXH0bC=> M2Oy[FI{PDByNUG5
THP1 MlvwRZBweHSxc3nzJGF{e2G7 NGjEeFcyKM7:TR?= NHq3W2EzPCCq NXTWelRIcW6mdXPld:Kh[2WubDDk[YF1cA>? MYCyN|QxODVzOR?=
SH-SY5Y MnfPSpVv[3Srb36gRZN{[Xl? MVeyOVAhdk1? NWPHcVQ3OTZiaB?= M1TZbINp[W6pZYOg[ZhxemW|c3nvckBx[XS2ZYLuJI9nKGenbnXzJIlvfm:udnXkJIlvKGOqb3zld5Rmem:uIIP5cpRp\XOrczygeZB1[WunIHHu[EBm\m[udYi= Mm\mNlM{OjZ2MkK=
HEK293 MkX1SpVv[3Srb36gRZN{[Xl? Mor3NUDDvU4EoB?= NYfuWWY2OThiaNMg M4HiVolvcGmkaYTzJJRp\SCtYXzpdolvNTdvbXXkbYF1\WRicnXjdpVqfG2nboSgc4Yhe3mwcHjpcIlvNTFiYXfndoVo[XSnczDpcpRwKGGpZ4Lld49u\XN? MkjBNlMzQDR6NEi=
HTK NVPpT|VxTnWwY4Tpc44hSXO|YYm= NW\ufG9DPDByIH7N M3XuRVczKGh? NEjTbFZqdmirYnn0d{BVT0ZvzsNihLNKdmS3Y3XkJG16d2[rYoLvZoxie3RiRHnm[oVz\W62aXH0bY9v NILtc5AzOzJ6NECwNi=>
HTK NGHERpBHfW6ldHnvckBCe3OjeR?= M{nlWlExOC16MEDuUS=> M3LIfFczKGh? MWricI9kc3NiVFfGMe6z6oDVSX7keYNm\CCUT2OgZY5lKEh{T{NCpGFk[3WvdXzheIlwdg>? MX:yN|I5PDByMh?=
Caco-2  Mkj2SpVv[3Srb36gRZN{[Xl? MUGxJOK2VcLi MVuyOEBp NETmW|ll\WO{ZXHz[ZMhW0WUVDDwdo91\WmwIHX4dJJme3Orb36= MlXKNlMyQTVyN{C=
HeLa M1rz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvG[48yODBibl2= NVXvcmRNOjRiaB?= M1LHbWROW09? NGnKdHpKSzVyIH;mJFExOG6P MlvGNlMyPjV5NEi=
HeLa NHn5V45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPrNYVpPDBibl2= NXHWdYh5PDhiaB?= M2ryfmROW09? M{mxUmlEPTBib3[gOFBvVQ>? M3HuTFI{OTZ3N{S4
HeLa NFz2e3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17EdlIxKG6P MmL2O|IhcA>? MXzEUXNQ M32wdWlEPTBib3[gNlBvVQ>? NEfxeHkzOzF4NUe0PC=>
HeLa MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfPNVAwOzBxNUCgcm0> NGfZcoE4OiCq MkC3SG1UVw>? M2HTWYlv[3KnYYPld{B1cGViboXtZoVzKG:oIF3NVEAp|pUQqH2pJIxwe3NiY3XscJMh\G:|ZTDk[ZBmdmSnboTsfS=> MnXVNlMyPjV5NEi=
MDA-MB-231 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3FNlUuPDByIH7N MYq0PEBp NW\ye|NRUUN3MDDv[kAzPjNwMn7NxsA> NGDLVWszOzB3NUG5PC=>
MCF-7  NGn3O2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXWyOU01ODBibl2= NEL0U|M1QCCq MYnJR|UxKG:oIEKyNE41dk1? M1:zfVI{ODV3MUm4
ECC-1  Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;ZNlExOCCwTR?= MlnGNlQhcA>? NIjiXnBmfGijbn;s MW\pcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{PSV? MYqyN|AzQDhyMx?=
HEC-1A NWfWbodFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHWfXR4OTByIH7N MlrqNlQhcA>? NGnZPYhmfGijbn;s NGfneXNqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB|OTW= NVT0dIZyOjNyMki4NFM>
NHAC-kn NU[1SJNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrPNVAwOTByL{WwNEBvVQ>? NF\TRo4yOiCq M2HMXWROW09? NXHNTXhvUUN3MDDv[kA2ODCwTR?= M2jHdVI{ODF5OEex
A549 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnCNlUxKG6P NYPZeY1ZPi15MjDo MX3EUXNQ Ml;4Z4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> NEDXdVgzOjl7NEe4NC=>
MG-63 M1znVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHxN|AxKG6P NH;yb3AyOiCq NEfCSnVFVVOR NGnaO4dqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hQDZn Mn;UNlI4QTl|M{i=
MG-63 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfvSHBnOzByIH7N NXewZW1vOjRiaB?= M2HicGROW09? NF\OcVdqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPjdn NIrwZWMzOjd7OUOzPC=>
MG-63 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvNNZZTOzByIH7N NFXyeZg1QCCq MW\EUXNQ M3\BSYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A2PiV? NVjNU|FMOjJ5OUmzN|g>
HL60  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33tTlE2OC1|NUCgcm0> MV6yOEBp NY[2PYZ{cW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? NWrlfHY5OjJ5NUO3N|k>
U937 Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rDblE2OC1|NUCgcm0> MWGyOEBp M{nZfolv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> MnTyNlI4PTN5M{m=
SCC-6 NXXXSXV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XFXFIxOC1|MkCwJI5O NVzVfIZbOTJxMkSvOFghcA>? MWjEUXNQ M{\kfolvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJI9nKFOFQz22JINmdGy|IHnuJIEh\G:|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= Mnu2NlI2PTJ|MkG=
U87  M1fYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXjNVAxNTNyMDDu[y=> MYKyOEBp MYXpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gO|ImKCCjdDCyNFBv\w>? NFHmWWYzOjJ5MEi0PS=>
K562 NWTobYlXTnWwY4Tpc44hSXO|YYm= NIrjXZkyKM7:TR?= Mn3zNVIhcA>? MmXWSG1UVw>? NVjzZWZT\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> MnTjNlIyPzlzOUi=
Reh MYPGeY5kfGmxbjDBd5NigQ>? MVewMlMwOSEQvF2= MoPzNVIhcA>? MX\EUXNQ M4H2SIVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS NF;NRlIzOjF5OUG5PC=>

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI, China|Sun Yat-sen University December 2016 Phase 1
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Unknown status Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID